Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Urology. 2014 Feb;83(2):369–375. doi: 10.1016/j.urology.2013.09.045

Table 3.

Test diagnostics of sample definitions of pathologic significance

Pathologic Findings (≥pT3 or Gleason >6 of Any Size)
Epstein’s Clinical Criteria Alone Significant Disease Insignificant Disease

Significant Disease 46 21 PPV = 69%

Insignificant Disease 12 25 NPV = 68%

Sensitivity = 79% Specificity = 54%

Pathologic Findings (≥pT3 or Gleason >6 of Any Size)
Epstein’s Clinical Criteria or ADC<850 µm2/sec Significant Disease Insignificant Disease

Significant Disease 54 25 PPV = 68%

Insignificant Disease 4 21 NPV = 84%

Sensitivity = 93% Specificity = 46%

Pathologic Findings (≥pT3, or Gleason ≥4+3, or Gleason 3+4 and ≥1.3 mL)
Epstein’s Clinical Criteria Alone Significant Disease Insignificant Disease

Significant Disease 44 23 PPV = 66%

Insignificant Disease 10 27 NPV = 73%

Sensitivity = 82% Specificity = 54%

Pathologic Findings (≥pT3, or Gleason ≥4+3, or Gleason 3+4 and ≥1.3 mL)
Epstein’s Clinical Criteria or ADC<850 µm2/sec Significant Disease Insignificant Disease

Significant Disease 52 27 PPV = 66%

Insignificant Disease 2 23 NPV = 92%

Sensitivity = 96% Specificity = 46%

Abbreviations as in Table 1.